Sano Chemicals
Sano Chemicals Inc is a clinical stage company focused on developing novel drug products to combat infectious diseases, especially antimicrobial resistant fungi and bacteria. Founded in 2012 in Bryan, Texas, near Texas A&M University, the company aims to create first-in-class treatments through rigorous research and development, addressing the global challenge of antimicrobial resistance (AMR). Their mission is to foster higher standards of care and improve quality of life by providing innovative solutions for infectious diseases and cancer.
Industries
Nr. of Employees
small (1-50)
Sano Chemicals
Patents
Synthesis of novel xylose free occidiofungin analogues and methods of using them
US-12102615-B2
View Details
Synthesis of novel xylose free occidiofungin analogues and methods of using them
US-12102615-B2
View DetailsProducts
Occidiofungin (antifungal natural product lead)
A first-in-class natural-product antifungal lead isolated from bacterial cultures, reported to be rapidly fungicidal and active against drug-resistant fungal pathogens; advanced through nonclinical studies with regulatory permission to proceed to Phase 1 clinical testing.
Mutacin (lantibiotic-derived antibacterial lead)
Lantibiotic analogs developed for treatment of Gram-positive infections; lead analogs have been identified with activity against MRSA and S. pneumoniae and demonstrated preclinical efficacy competitive with vancomycin in systemic infection models.
Occidiofungin (antifungal natural product lead)
A first-in-class natural-product antifungal lead isolated from bacterial cultures, reported to be rapidly fungicidal and active against drug-resistant fungal pathogens; advanced through nonclinical studies with regulatory permission to proceed to Phase 1 clinical testing.
Mutacin (lantibiotic-derived antibacterial lead)
Lantibiotic analogs developed for treatment of Gram-positive infections; lead analogs have been identified with activity against MRSA and S. pneumoniae and demonstrated preclinical efficacy competitive with vancomycin in systemic infection models.
Services
On-site cultivation of proprietary bacterial strains and downstream purification to produce lead compounds for preclinical and clinical programs.
Design and conduct of nonclinical toxicology and efficacy studies using rodent models to support safety and efficacy claims.
Preparation of regulatory applications and design of early-phase clinical protocols to enable Phase 1 studies.
Negotiation and management of licensing agreements and technology transfer to commercial and agricultural partners.
On-site cultivation of proprietary bacterial strains and downstream purification to produce lead compounds for preclinical and clinical programs.
Design and conduct of nonclinical toxicology and efficacy studies using rodent models to support safety and efficacy claims.
Preparation of regulatory applications and design of early-phase clinical protocols to enable Phase 1 studies.
Negotiation and management of licensing agreements and technology transfer to commercial and agricultural partners.
Expertise Areas
- Antifungal drug discovery from natural products
- Antibacterial lantibiotic and peptide therapeutic development
- Preclinical toxicology and efficacy studies
- Early-phase clinical development and IND submissions
Key Technologies
- Natural-product isolation and purification
- Microbial fermentation and bioreactors
- Upstream and downstream bioprocessing
- Lantibiotic/lanthipeptide engineering
News & Updates
Dr. Miles presented Sano Chemicals' new first-in-class antifungal drug Occidiofungin - The Fungus KillerTM at the Biotech Showcase 2024 in San Francisco.
Dr. Smith presented a talk titled: "Preclinical Development of a First-In-Class Antifungal, Occidiofungin, for the Treatment of Serious Fungal Infections".
FDA grants Qualified Infectious Disease Product and Fast-track designation for OCF001 drug product for the treatment of recurrent vulvovaginal candidiasis (RVVC).
FDA IND application (IND 160729) for OCF001 received permission to proceed with Phase 1 clinical testing.
Geng M, Hansanant N, Lu SE, Lockless SW, Shin R, Orugunty R, Smith L. Front Microbiol. 2022 Dec 13;13:1056453.
Hansanant N, Smith L. Antibiotics (Basel). 2022 Aug 23;11(9):1143.
Dr. Miles presented Sano Chemicals' new first-in-class antifungal drug Occidiofungin - The Fungus KillerTM at the Biotech Showcase 2024 in San Francisco.
Dr. Smith presented a talk titled: "Preclinical Development of a First-In-Class Antifungal, Occidiofungin, for the Treatment of Serious Fungal Infections".
FDA grants Qualified Infectious Disease Product and Fast-track designation for OCF001 drug product for the treatment of recurrent vulvovaginal candidiasis (RVVC).
FDA IND application (IND 160729) for OCF001 received permission to proceed with Phase 1 clinical testing.
Geng M, Hansanant N, Lu SE, Lockless SW, Shin R, Orugunty R, Smith L. Front Microbiol. 2022 Dec 13;13:1056453.
Hansanant N, Smith L. Antibiotics (Basel). 2022 Aug 23;11(9):1143.